![]() ![]() Transdermal patch treatment can be resumed at the same dose if treatment is not interrupted for more than three days. Treatment should be temporarily interrupted if gastrointestinal adverse reactions are observed until these adverse reactions resolve. The clinical benefit of rivastigmine should be reassessed on a regular basis.ĭiscontinuation should also be considered when evidence of a therapeutic effect at the optimal dose is no longer present. If well tolerated and only after a minimum of six months of treatment at 9.5 mg/24 h, the treating physician may consider increasing the dose to 13.3 mg/24 h in patients who have demonstrated a meaningful cognitive deterioration (e.g.ĭecrease in the MMSE) and/or functional decline (based on physician judgement) while on the recommended daily effective dose of 9.5 mg/24 h (see section 5.1). ![]() Dose escalation 9.5 mg/24 h is the recommended daily effective dose which should be continued for as long as the patient continues to demonstrate therapeutic benefit. Maintenance dose After a minimum of four weeks of treatment and if well tolerated according to the treating physician, the dose of 4.6 mg/24 h should be increased to 9.5 mg/24 h, the daily recommended effective dose, which should be continued for as long as the patient continues to demonstrate therapeutic benefit. Transdermal patches Rivastigmine in vivo release rates per 24 h Exelon 4.6 mg/24 h 4.6 mg Exelon 9.5 mg/24 h 9.5 mg Exelon 13.3 mg/24 h 13.3 mg Initial dose Treatment is started with 4.6 mg/24 h. The outside of the backing layer is beige and labelled with ∾xelon, ∱3.3 mg/24 h and ∼NFU. The outside of the backing layer is beige and labelled with ∾xelon, ∹.5 mg/24 h and ∻HDI.Įxelon ® 13.3 mg/24 h transdermal patch: Each transdermal patch is a thin, matrix-type transdermal patch consisting of three layers. Exelon 9.5 mg/24 h transdermal patch: Each transdermal patch is a thin, matrix-type transdermal patch consisting of three layers. The outside of the backing layer is beige and labelled with ∾xelon, ∴.6 mg/24 h and ∺MCX. Transdermal patch Exelon 4.6 mg/24 h transdermal patch: Each transdermal patch is a thin, matrix-type transdermal patch consisting of three layers. #LOQUENDO TTS 7 PATCH EXE FULL#For the full list of excipients, see section 6.1. Each transdermal patch of 15 cm2 contains 27 mg of rivastigmine. ![]() Each transdermal patch of 10 cm 2 contains 18 mg of rivastigmine.Įxelon ® 13.3 mg/24 h transdermal patch: Each transdermal patch releases 13.3 mg of rivastigmine per 24 hours. Each transdermal patch of 5 cm 2 contains 9 mg of rivastigmine.Įxelon 9.5 mg/24 h transdermal patch: Each transdermal patch releases 9.5 mg of rivastigmine per 24 hours. Loquendo: MRCP - TTS Engine 7.20.7.Įxelon 4.6 mg/24 h transdermal patch: Each transdermal patch releases 4.6 mg of rivastigmine per 24 hours. Tested with Loquendo Speech Suite 7.0.18 Patch 3. Vocalizer TTS Voice v1.0.5 Text-to-Speech engine.apk. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |